Close menu




June 30th, 2020 | 16:14 CEST

CENIT, SYZYGY, Triumph Gold - business models with upside potential

  • Investments
Photo credits: pixabay.com

A well-diversified portfolio should always include different industries and regions. Depending on the investment horizon and risk profile, a wide range of investment opportunities are available on the capital market. In addition to well-known large companies, there are also interesting small companies that are on a growth path and may offer attractive price potential. Consulting, software and gold - and what else interested investors need to know.

time to read: 3 minutes | Author: Mario Hose
ISIN: CA8968121043 , DE0005104806 , DE0005407100

Table of contents:


    Forecasts, target price and rating confirmed

    CENIT has been successfully active for over 25 years as a leading consulting and software specialist for the optimization of business processes in the fields of Digital Factory, Product Lifecycle Management (PLM), SAP PLM, Enterprise Information Management (EIM), Business Optimization & Analytics (BOA) and Application Management Services (AMS). Standard solutions from strategic partners such as DASSAULT SYSTEMES, SAP and IBM complement CENIT with established, proprietary software developments. The company is represented worldwide at 17 locations in six countries with over 700 employees. They work for customers in the automotive, aerospace, mechanical engineering, tool and mould making, financial services, retail and consumer goods industries, among others.

    With the publication of the Q1 report 2020, CENIT AG is still showing a comparatively solid business development. On the sales level, the company shows a slight decline of -4.9% to EUR 39.23 million (previous year: EUR 41.24 million), which was accompanied by a decline in EBIT of -4.7% to EUR 0.81 million (previous year: EUR 0.85 million). In absolute terms, both sales and earnings development were comparatively constant, particularly as CENIT AG was also negatively affected by the Covid 19 pandemic in the first quarter. With the publication of the Q1 report, the CENIT Executive Board does not consider itself in a position to make a concrete sales and earnings forecast due to the currently difficult situation to assess. Nevertheless, the analysts of GBC Research confirm their forecasts from April 16, 2020, according to which they expect a 20% decline in sales to EUR 137.37 m in 2020. On the basis of this estimation they confirm their price target of EUR 18.10 per share and continue to assign a ‚buy' rating.

    German companies continue growth course

    SYZYGY is one of the leading consulting and implementation partners for the transformation in marketing and sales. SYZYGY creates, orchestrates and designs digital experiences and products for brands, companies and people. Strategy, products and activation are the central services of the group. Technology is the connecting and scaling element. The main focus of activity is on strategic consulting, conception and design, technical realisation of brand platforms, business applications, websites, hosting, digital campaigns and mobile apps. Customers include renowned brands such as AVIS, BMW, Commerzbank, Consorsbank, Daimler, Deutsche Bank, Kyocera, Lufthansa, Mazda, Miles & More, o2, Paypal, Porsche, Techniker Krankenkasse and Volkswagen.

    As expected, SYZYGY's sales revenue in the first quarter of 2020 was only slightly down on the previous year, at EUR 14.93 million (PY: EUR 15.69 million). According to analysts at GBC Research, the effects of the increasing spread of SARS-CoV-2 are already visible here to a moderate extent. Furthermore, a decline in spending behaviour by customers is expected, particularly in the current second quarter of 2020. As in previous periods, the sales revenues of the SYZYGY companies operating in Germany rose again, by +6.3% to EUR 12.28 million (previous year: EUR 11.55 million). As expected, the -4.9% decline in sales was followed by a 23.9% decline in EBIT to EUR 1.10 million (previous year: EUR 1.44 million). The experts at GBC confirm their price target of EUR 9.25 per share and continue to assign a ‚buy' rating.

    Personnel changes at the top

    Triumph Gold Corp. from Canada specialises in the exploration and development of precious metal deposits. The company aims to increase shareholder value by expanding the regional Freegold Mountain project in Yukon, Canada. Yesterday, the company announced that Tony Barresi has resigned as Director and President. Barresi will remain with the company as a technical advisor. "We are thankful for the contributions Tony has made at advancing all of our projects and fortunate for his continued support working with Jesse Halle, our VP, exploration," stated Chairman John Anderson.

    In addition, Triumph Gold is pleased to announce that Mr. Brian Bower has assumed the position of Lead Director. Mr. Bower has more than 30 years of experience as an exploration and mining geologist and has been primarily active in British Columbia and the Yukon. "Mr. Bower's extensive experience in supporting strong technical teams were instrumental in developing projects like the New Afton mine, the Kemess South deposit, the Blackwater project and the Mount Milligan deposit in British Columbia. He has also worked on the Casino deposits advanced exploration program in the Yukon," said Mr. Anderson. "We are excited to have Brian join us as an active participant in expanding our team and rapidly growing the company beyond its exploration stage. This is a great step forward for Triumph Gold Corp."


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Stefan Feulner on October 4th, 2022 | 11:59 CEST

    RWE, Pathfinder Ventures, United Internet - Panic as an opportunity

    • Camping
    • Investments

    Last week, the crash prophets crawled out of their caves and outdid themselves with forecasts reaching the Corona lows at around 8,000 points in the leading German DAX index. Without a doubt, the general conditions for a sustained stock rally are moderate with the escalation of the Ukraine situation and concerns about further interest rate hikes. Nevertheless, there are attractive entry opportunities at the current level, which could pay off in cash in the long term.

    Read

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read